RS-Glucoraphanin bioactivated with myrosinase treatment counteracts proinflammatory cascade and apoptosis associated to spinal cord injury in an experimental mouse model

Maria Galuppo, Sabrina Giacoppo, Gina Rosalinda De Nicola, Renato Iori, Emanuela Mazzon, Placido Bramanti

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Spinal cord injury (SCI) is a highly debilitating pathology. Although innovative medical care has been improved, drug therapies to counteract neuronal damage and promote regeneration are limited. An experimental mouse model of SCI was designed to examine the possible neuroprotective role of the glucosinolate (RS)-glucoraphanin (RS-GRA), bioactivated with myrosinase enzyme (MYR-activated RS-GRA). Methodologically, the injury was induced by application of an aneurysm clip (force of 24g) for 1 min via four-level T5-T8 after laminectomy. MYR-activated RS-GRA was administered in mice (10 mg/kg i.p.) 1 and 6 h after the trauma, identified as the therapeutic intervention window. The treatment with MYR-activated R S-GRA significantly decreased histological damage resulted by proinflammatory events as well as by apoptosis cascade. Overall, by quantitative analysis of immunohistochemical images, the neuroprotection has been quite evident. MYR-activated RS-GRA has given a histological quantification around zero in all determinations. Particularly, looking at the strongest data obtained, regarding the glial fibrillary acidic protein (GFAP), result the high tissue localization of this damage marker mediated by astrocyte activity, estimated as about 80% of positive staining, was shot down by MYR-activated RS-GRA treatment. Taken together, our results show that MYR-activated RS-GRA could represent an interesting approach for the management of secondary damage following SCI.

Original languageEnglish
Pages (from-to)88-96
Number of pages9
JournalJournal of the Neurological Sciences
Volume334
Issue number1-2
DOIs
Publication statusPublished - Nov 15 2013

Fingerprint

Spinal Cord Injuries
Theoretical Models
Apoptosis
Therapeutics
Glucosinolates
Laminectomy
Glial Fibrillary Acidic Protein
Wounds and Injuries
Surgical Instruments
Astrocytes
Aneurysm
glucoraphanin
thioglucosidase
Regeneration
Pathology
Staining and Labeling
Drug Therapy
Enzymes

Keywords

  • Apoptosis
  • Bioactive (R)-glucoraphanin
  • Inflammation
  • Myrosinase enzyme
  • Proinflammatory cytokines
  • Spinal cord injury

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

RS-Glucoraphanin bioactivated with myrosinase treatment counteracts proinflammatory cascade and apoptosis associated to spinal cord injury in an experimental mouse model. / Galuppo, Maria; Giacoppo, Sabrina; De Nicola, Gina Rosalinda; Iori, Renato; Mazzon, Emanuela; Bramanti, Placido.

In: Journal of the Neurological Sciences, Vol. 334, No. 1-2, 15.11.2013, p. 88-96.

Research output: Contribution to journalArticle

@article{fd6ed208207946f2bb8a778cd3cd4cfe,
title = "RS-Glucoraphanin bioactivated with myrosinase treatment counteracts proinflammatory cascade and apoptosis associated to spinal cord injury in an experimental mouse model",
abstract = "Spinal cord injury (SCI) is a highly debilitating pathology. Although innovative medical care has been improved, drug therapies to counteract neuronal damage and promote regeneration are limited. An experimental mouse model of SCI was designed to examine the possible neuroprotective role of the glucosinolate (RS)-glucoraphanin (RS-GRA), bioactivated with myrosinase enzyme (MYR-activated RS-GRA). Methodologically, the injury was induced by application of an aneurysm clip (force of 24g) for 1 min via four-level T5-T8 after laminectomy. MYR-activated RS-GRA was administered in mice (10 mg/kg i.p.) 1 and 6 h after the trauma, identified as the therapeutic intervention window. The treatment with MYR-activated R S-GRA significantly decreased histological damage resulted by proinflammatory events as well as by apoptosis cascade. Overall, by quantitative analysis of immunohistochemical images, the neuroprotection has been quite evident. MYR-activated RS-GRA has given a histological quantification around zero in all determinations. Particularly, looking at the strongest data obtained, regarding the glial fibrillary acidic protein (GFAP), result the high tissue localization of this damage marker mediated by astrocyte activity, estimated as about 80{\%} of positive staining, was shot down by MYR-activated RS-GRA treatment. Taken together, our results show that MYR-activated RS-GRA could represent an interesting approach for the management of secondary damage following SCI.",
keywords = "Apoptosis, Bioactive (R)-glucoraphanin, Inflammation, Myrosinase enzyme, Proinflammatory cytokines, Spinal cord injury",
author = "Maria Galuppo and Sabrina Giacoppo and {De Nicola}, {Gina Rosalinda} and Renato Iori and Emanuela Mazzon and Placido Bramanti",
year = "2013",
month = "11",
day = "15",
doi = "10.1016/j.jns.2013.07.2514",
language = "English",
volume = "334",
pages = "88--96",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - RS-Glucoraphanin bioactivated with myrosinase treatment counteracts proinflammatory cascade and apoptosis associated to spinal cord injury in an experimental mouse model

AU - Galuppo, Maria

AU - Giacoppo, Sabrina

AU - De Nicola, Gina Rosalinda

AU - Iori, Renato

AU - Mazzon, Emanuela

AU - Bramanti, Placido

PY - 2013/11/15

Y1 - 2013/11/15

N2 - Spinal cord injury (SCI) is a highly debilitating pathology. Although innovative medical care has been improved, drug therapies to counteract neuronal damage and promote regeneration are limited. An experimental mouse model of SCI was designed to examine the possible neuroprotective role of the glucosinolate (RS)-glucoraphanin (RS-GRA), bioactivated with myrosinase enzyme (MYR-activated RS-GRA). Methodologically, the injury was induced by application of an aneurysm clip (force of 24g) for 1 min via four-level T5-T8 after laminectomy. MYR-activated RS-GRA was administered in mice (10 mg/kg i.p.) 1 and 6 h after the trauma, identified as the therapeutic intervention window. The treatment with MYR-activated R S-GRA significantly decreased histological damage resulted by proinflammatory events as well as by apoptosis cascade. Overall, by quantitative analysis of immunohistochemical images, the neuroprotection has been quite evident. MYR-activated RS-GRA has given a histological quantification around zero in all determinations. Particularly, looking at the strongest data obtained, regarding the glial fibrillary acidic protein (GFAP), result the high tissue localization of this damage marker mediated by astrocyte activity, estimated as about 80% of positive staining, was shot down by MYR-activated RS-GRA treatment. Taken together, our results show that MYR-activated RS-GRA could represent an interesting approach for the management of secondary damage following SCI.

AB - Spinal cord injury (SCI) is a highly debilitating pathology. Although innovative medical care has been improved, drug therapies to counteract neuronal damage and promote regeneration are limited. An experimental mouse model of SCI was designed to examine the possible neuroprotective role of the glucosinolate (RS)-glucoraphanin (RS-GRA), bioactivated with myrosinase enzyme (MYR-activated RS-GRA). Methodologically, the injury was induced by application of an aneurysm clip (force of 24g) for 1 min via four-level T5-T8 after laminectomy. MYR-activated RS-GRA was administered in mice (10 mg/kg i.p.) 1 and 6 h after the trauma, identified as the therapeutic intervention window. The treatment with MYR-activated R S-GRA significantly decreased histological damage resulted by proinflammatory events as well as by apoptosis cascade. Overall, by quantitative analysis of immunohistochemical images, the neuroprotection has been quite evident. MYR-activated RS-GRA has given a histological quantification around zero in all determinations. Particularly, looking at the strongest data obtained, regarding the glial fibrillary acidic protein (GFAP), result the high tissue localization of this damage marker mediated by astrocyte activity, estimated as about 80% of positive staining, was shot down by MYR-activated RS-GRA treatment. Taken together, our results show that MYR-activated RS-GRA could represent an interesting approach for the management of secondary damage following SCI.

KW - Apoptosis

KW - Bioactive (R)-glucoraphanin

KW - Inflammation

KW - Myrosinase enzyme

KW - Proinflammatory cytokines

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=84887465716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887465716&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2013.07.2514

DO - 10.1016/j.jns.2013.07.2514

M3 - Article

C2 - 23992921

AN - SCOPUS:84887465716

VL - 334

SP - 88

EP - 96

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -